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1. Introduction 
Pyrrole–imidazole polyamides (PI polyamides) are ligands that 
bind to the DNA minor groove with high affinity and sequence 
specificity. These contain N-methylpyrrole (P) and N-
methylimidazole (I), and recognize each of the four Watson–Crick 
base pairs uniquely.1–3 The binding rule of PI polyamides, termed 
Dervan’s rule, is the recognition of a G/C base pair by antiparallel 
pairing of an I/P, whereas a P/P pair recognizes an A/T or a T/A 
base pair. A -alanine/-alanine (/) pair reads an A/T or a T/A 
base pair in the same way as a P/P pair does. Recently, the 
introduction of PI polyamides into DNA-alkylating agents has 
attracted attention because of their sequence-specific alkylation at 
target sites.4 
Trinucleotide repeat sequences exist in some regions of 
genomic DNA, and the expansion of the repeat sequences often 
causes neurological disorders.5,6 For example, the expansion of 
CAG trinucleotide repeats within the first exon of the Huntingtin 
(HTT) gene (from 36 to > 100 repeats) yields a full-length HTT 
protein harboring expanded polyglutamine tracts, which gain some 
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functions, lead to the selective disruption of neuronal protein 
function, and ultimately, cause Huntington’s disease.7,8,9 In 
myotonic dystrophy type 1 (DM1) and Huntington’s disease-like 
2, which are associated with CTG repeat sequences located in the 
3 UTR of genes, transcriptional products containing excess CUG 
repeats accumulate within the nucleus and form a 1 bp mismatch-
containing hairpin structure, bind to proteins such as splicing 
regulators, cause inactivation of their alternative pre-mRNA 
splicing, and lead to the pathogenesis of each of these diseases.10–
13 Surprisingly, these trinucleotide repeat sequences have a 
tendency to expand as a result of the formation of a hairpin-like 
structure containing a d(CAG/CAG) or d(CTG/CTG) 1 bp 
mismatch internal loop motif, by reannealing during DNA 
replication, repair, and recombination. The expansion leads to a 
decreased age of onset and increased severity of the diseases in 
successive generations.5 Several mechanisms to explain this 
characteristic inheritance have been proposed; however, a genuine 
one remains unknown. Recently, studies on antisense 
oligonucleotides that target the internal loop motifs located in the 
hairpin structure have been reported.13 Moreover, Disney and 
coworkers reported previously that covalent adduct formation 
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between expanded rCUG transcripts in the hairpin structure and 
moieties that target the r(CUG/CUG) mismatch internal loop motif 
improved DM1-associated pre-mRNA splicing defects.14 In 
addition, Nakatani et al. developed a small molecule that binds a 
hairpin d(CAG/CAG) region and flips cytidine nucleotides out.15 
Despite those studies, to our knowledge, there are few reports of 
the targeting of Watson–Crick base pairs in CAG/CTG repeat 
regions, which are present even in disease-associated expanded 
CAG/CTG repeats. Our laboratory has developed polyamides with 
fluorescence dyes that detect CAG repeated sequences as a 
diagnostic tool.16,17 
Based on these reports, we hypothesized that the inhibition of 
transcripts at CAG/CTG repeat sequences that form Watson–Crick 
base pairs, via specific covalent adduction of an alkylating agent 
possessing polyamides that recognizes CAG/CTG repeat 
sequences may prevent the subsequent occurrence of expanded 
polyglutamine tracts and the sequestration of expanded rCUG 
transcripts.18 Moreover, Sinden and coworkers reported that DNA 
damaging agents, such as alkylating agents, UV irradiation, and 
oxidation, increase the rate of triplet repeat deletion.19,20 These are 
effective approaches for genetic disorders, but have a very limited 
DNA sequence specificity, which must be related to side effects. 
To suppress it, we also hypothesized that sequence-specific 
alkylation damage may lead to an increase in the rate of 
d(CAG/CTG) repeat deletion without damaging other sequences. 
Our laboratory reported previously that polyamides covalently 
linked to DNA-alkylating agents predominantly alkylated their 
targeting sequences that are associated with cancer (5–
(GGGTTA)n–3, human telomere repeat sequences,21–23 or 5–
ACGTCACCA–3 in KRAS codon 13 mutation24). In the present 
study, we synthesized PI polyamides conjugated to a DNA-
alkylating agent, chlorambucil (Chl), to target CAG/CTG repeat 
sequences, and their length of sequence recognition was elongated 
by introducing novel building blocks used in Fmoc solid-phase 
peptide synthesis (SPPS).25 The activities of the compounds 
obtained were investigated in terms of DNA sequence-specific 
alkylation, transcriptional inhibition, and dynamics of the 
interaction with the target sequence. 
2. Results and discussion 
2.1. Molecular design and synthesis 
We rationally designed three types of PI polyamide–Chl 
conjugates (1–4) to target CAG/CTG repeat sequences with 
different lengths or structures (Figure 1).26,27 Chl is a nitrogen 
mustard alkylating agent that belongs to the group of anticancer 
drugs and has been used widely as a first line of treatment for 
chronic lymphocytic leukemia. Its efficacy has been confirmed at 
the clinical level.28,29 The potency of hairpin PI polyamide–Chl 
conjugates has been investigated in terms of chemical and 
biological activity.30,31 Hartley and coworkers previously 
demonstrated preferential alkylation at the N3 of guanine or 
adenine on 5–TTTTGG–3 or 5–TTTTGA–3 sequences, 
respectively, by tripyrrole conjugated with BAM,32 which is one 
of the nitrogen mustards. In addition, it has been reported that Chl 
is more cytotoxic than BAM in the human colonic adenocarcinoma 
LS174T and leukemic K562 cell lines.33 
From these reports, we inferred that hairpin PI polyamide–Chl 
conjugates, the specific alkylation of which at the N3 of guanines 
has never been investigated, were appropriate for targeting AG-
rich sequences as alkylating agents. Moreover, the flexibility of 
Chl within the structure may allow reaching the opposite strand.34 
To promote this function and the alkylation at guanines or 
adenines of both strands by Chl moieties, -alanine and 
subsequently 3,3-diamino-N-methyldipropylamine (DMDPA; as 
a relatively long linker, to obtain additional flexibility) were added 
to the C terminus. We also designed PI polyamides to allow them 
to have symmetry and therefore the polyamides binds the match 
sequence in two orientations.30 This leads to an increase in the 
number of alkylating sites, which are placed on either side of the 
binding site. The appropriate positions of PI polyamide moieties 
were linked with -alanine, which allows for optimal H-bond 
donor/acceptor interactions while retaining flexibility, resulting in 
an increase in overall affinity and specificity.35–38  
Regarding the synthesis of long-chain hairpin PI polyamides, 
only monomeric or/and dimeric units have been used in Fmoc 
SPPS to produce relatively long hairpin polyamides;39 therefore, 
their yields were worse because of the increase in the number of 
reaction steps. In particular, Fmoc SPPS had difficulty in coupling 
with a P after the introduction of a GABA (-turn) , which 
functions to transform polyamides into hairpin structures that 
allow high affinity and specificity.24,40 To overcome these 
difficulties, we plan to synthesize FmocHN-P--CO2H (5), Boc-D-
Dab (FmocHN-P)-CO2H (6), and FmocHN-P--I-CO2H (10) as 
building blocks of Fmoc SPPS in solution phase,39,41,42 in which 
time-consuming purifications are never required in any of the 
reaction steps (Scheme 1). All of them are washed and dried to 
produce powder states that can then be subjected to Fmoc SPPS 
without further purification. Compound 5 and 6, which were used 
in Fmoc SPPS of polyamide 13 and 14, respectively (Scheme 2), 
played an important role in preventing the P-lacking products and 
could be prepared using only one step. As compound 10 was used 
to construct a core moiety of the parent polyamide in this study, its 
introduction into Fmoc SPPS, in addition to that of compound 5 or 
6, enabled a great reduction in reaction steps (from 17 to eight 
steps)(Scheme 2). Consequently, we succeeded in reducing failure 
sequence products and enhanced the yield of the reaction. As we 
Figure 1. A  (a) Chemical structure of PI polyamide–chlorambucil (Chl) 
conjugates (1–4) targeting the CAG/CTG repeat sequences  (b) Schematic 
representation of the binding models of conjugates 1–4 to the CAG/CTG 
repeat region via a dimer (conjugate 1) or hairpin (conjugate 2–4) 
conformation. 
anticipated that it was less difficult for such a long-chain 
polyamide in a hairpin structure to be formed into the open state, 
we performed a chiral substitution of the -turn by an amino group 
(to produce polyamide 15 and conjugate 4).2,43 
The products obtained by programmable Fmoc SPPS 
introducing the building blocks were cleaved with DMDPA, to 
produce the amino PI polyamides 11–14 (Scheme 2). Conjugates 
1–3 were produced via the PyBOP coupling with Chl. By 
conversion from 14, the PI polyamide–Chl conjugate 4 was 
synthesized via the deprotection of the Boc group by TFA-DCM 
in the last step. The diamino PI polyamide 15 was also prepared 
by acid deprotection for SPR assays. Conjugates 1–4 were purified 
by reversed-phase HPLC, and confirmed by ESI-TOF-MS. 
2.2. DNA-alkylating activity of conjugates 1-4 
First, The DNA-alkylating activities of conjugates 1–3 were 
evaluated using polyacrylamide gel electrophoresis (PAGE), to 
investigate the effects of the structure or recognition length of PI 
polyamides on specific alkylation within CAG/CTG repeat 
sequences.44,45 5-Texas Red-labeled 214 bp DNA fragments 
including a (CAG/CTG)12 repeat sequence were prepared by 
transformation into pGEM-T Easy vectors, and subsequently by 
PCR amplification and purification (Figure S1).46 Alkylation was 
carried out at 23°C for 18 h, followed by quenching by the addition 
of calf thymus DNA. The samples were heated at 95°C under 
neutral conditions for 10 min. Under these conditions, all the N3 
of purines at the alkylated sites in the DNA fragment produced 
cleavage bands quantitatively on the gel.47,48 
The results of the sequencing gel analysis of the DNA fragment 
treated with conjugates 1–3 are shown in Figure 2. Regarding the 
alkylation of the (CAG)12 repeat sequence (Figure 2a), no 
alkylation by conjugates 1 and 2 occurred at the sites of the CAG 
repeat, and  alkylation by conjugate 1 occurred at site a, which can 
be explained by recognition of expanded state with 1 bp mismatch, 
instead of dimer recognition.49 Even at 10 times concentrations, 
conjugate 1 did not specifically alkylate the CAG repeat sequence 
(data not shown). At around 150 nanomolar concentrations, 
alkylation by conjugate 2 occurred within the CAG repeat, albeit 
with a specificity that was much lower than that of conjugate 3 
(data not shown). However, we observed specific alkylation by 
conjugate 3 at sites of the target region with higher alkylating 
activities and sequence specificity at nanomolar concentrations 
(lanes 2–5), except alkylation at site b with 3 bp mismatch. 
Conversely, within the (CTG)12 repeat sequence (Figure 2b), we 
observed specific alkylation by both conjugates 2 and 3, except 
alkylation at site c and d with 3 bp mismatch by conjugate 2 and 3, 
respectively, and no alkylation by conjugate 1. These results 
indicate that, although 8 bp recognition through dimer (conjugate 
1) or hairpin (conjugate 2) conformation is not sufficient, 11 bp 
recognition through hairpin conformation (conjugate 3) is required 
for sequence-specific alkylation in both strands including 
CAG/CTG repeat sequences.  
Next, having established that, among conjugates 1–3, conjugate 
3 is the most appropriate for targeting CAG/CTG repeat sequences, 
we used conjugates 3 and 4 to investigate DNA-alkylating 
activities for CAG/CTG repeat sequences in detail and the effect 
of chiral substitution at the  position of the -turn by an amino 
group on DNA-alkylating activities. The results of the sequencing 
gel analysis using a similar treatment to that mentioned above are 
shown in Figure 3. The (CAG/CTG)12-containing DNA fragment 
prepared in this study comprised the target region (5–
(CAG)12CAA–3/5–TTG(CTG)12–3) for these conjugates (Figure 
3c). In fact, specific alkylation by conjugates 3 and 4 was observed 
within the target region between sites 1 and 13, or sites 1’ and 15’, 
except non-specific alkylation (site b and site d) as also seen in 
Figure 2 (Figure 3). For the CTG repeat sequence (Figure 3b), both 
conjugates alkylated at the N3 position of the guanines in the CTG 
trinucleotides, particularly from the third CTG (site 6’) to the fifth 
Scheme 1. (i) HCTU, DIEA, DMF, and then a solution of GABA in DIEA 
and DMF, rt, 3 h, 94%; (ii) PyBOP, DIEA, DMF, and then a solution of Boc-
D-Dab-OH in DMF, rt, 3 h, quant; (iii) BocHN--alanine, HCTU, DIEA, 
DMF, rt, 1.5 h, 84%; (iv) TFA, H2O, rt, then NaOH, MeOH, H2O, 40°C, 2 h; 
(v) a solution of FmocHN-P-CO2H and HCTU in DIEA and DMF, rt, 6 h, 
73%. 
Scheme 2. (i) Fmoc solid-phase synthesis of 11: FmocHN-P-CO2H, 10, 
FmocHN-I-CO2H (in this order, total three steps), 20% piperidine, HCTU, 
DIEA, DMF, NMP in each step; (ii) DMDPA; (iii) Chl, PyBOP, DIEA, DMF, 
rt; (iv) Fmoc solid-phase synthesis of 12: FmocHN-P-CO2H, 10, FmocHN-I-
CO2H, 5, 10, FmocHN-I-CO2H (in this order, total six steps), 20% piperidine, 
HCTU, DIEA, DMF, NMP in each step; Fmoc solid-phase synthesis of 13 (14): 
FmocHN-P-CO2H, 10, 10, FmocHN-I-CO2H, 5 (6), 10, 10, FmocHN-I-CO2H 
(in this order, total eight steps), 20% piperidine, HCTU, DIEA, DMF, NMP in 
each step; (v) TFA-DCM, rt; (vi) Chl, HCTU, DIEA, DMF, then TFA-DCM, 
0 oC. 
CTG trinucleotide (site 8’) numbered from the 5 side. These sites 
are included in ones which can be alkylated by the conjugates 
through two binding modes (site 6’ to 11’), thus showing the 
relative higher cleavage intensities (Figure 3c). In total, we 
observed 15 cleavage bands as a result of the N3 adenine or 
guanine alkylation, which corresponded to prospective alkylating 
sites within the target region (Figure 3b and c). Conversely, 
specific alkylation by conjugates 3 and 4 within the CAG repeat 
occurred similarly and produced 14 cleavage bands. As with the 
case for the CTG repeats, the cleavage bands with the relatively 
higher intensities (site 4 to 9) mostly correspond to the sites which 
can be alkylated by the conjugates through two binding modes 
(site 4 to 10). In addition, we observed that these cleavage bands 
on the gel were a little broader than those obtained for the CTG 
repeat, which suggests that both N3 adenines and their adjacent 
guanines in CAG trinucleotides were specifically alkylated by 
conjugates 3 and 4 (Figure 3a and c). We found that, although the 
effect of a chiral substitution on DNA-alkylating activities was not 
observed in this experimental system, rationally designed long-
chain PI polyamide–Chl conjugates with a relatively long linker 
had the ability to alkylate both of the strands and increase the 
number of the alkylating sites by binding in the two orientations. 
2.3. The effect of conjugate 4 on transcription 
To examine the influence of alkylation by a PI polyamide–Chl 
conjugate on transcription, non-labelled DNA fragments including 
a (CAG/CTG)12 repeat (sequences A and B, as shown in Figure 4a) 
were treated with conjugate 4 and its parent  polyamide 15 as a 
control, and then transcribed by T7 RNA polymerase. The DNA 
fragments were prepared by a similar method for the sequence gel 
analysis. Sequence B was prepared by inserting a (CAG/CTG)12 
repeat and its sequence is the same as that used in the sequencing 
gel analysis. Sequence A was prepared by inserting a inversed 
(CAG/CTG)12 repeat (Figure 4a and S2). Its transcripts were 
analyzed by 10% denaturing PAGE,50 and the results of the gel 
stained with SYBR Gold are shown in Figure 4b and c. In only 
lanes 2–4 of figure 4b and c, in addition to full-length RNAs 
(predicted length: 197 nt), truncated RNAs (predicted length : Ca. 
60–101 nt) appeared as ladder-like bands in a dose-dependent 
manner, suggesting that conjugate 4 alkylated  the CAG/CTG 
repeat region and arrest the progression of RNA polymerase at the 
alkylating sites. Furthermore, we observed that within the target 
region, the number of the ladder-like bands obtained from 
transcription of sequence A was greater than that obtained from 
sequence B. this shows the alkylation by conjugate 4 at both 
adenines and guanines in the (CAG)12 repeat, which corresponds 
to the results of the sequence gel analysis (Figure 3a). Moreover, 
this observation demonstrates that alkylation of the template 
Figure 2. Thermally induced strand cleavage of 214 bp DNA fragments derived from 5-Texas Red-labeled strands including (a) a (CAG)12 or (b) (CTG)12 repeat 
(8 nM) by conjugates 1, 2, and 3 at 23°C for 18 h. These two DNA strands are complementary. Lane 1: DNA control; lanes 2–5: 2.5, 5, 10, and 20 nM of 3; lanes 
6–9: 2.5, 5, 10, and 20 nM of 2; lanes 10–13: 2.5, 5, 10, and 20 nM of 1. (c) Schematic representation of the recognition and alkylation models of these conjugates. 
The arrows indicate the alkylating sites that were inferred from the sequencing gel analysis. Note that alkylation does not occur at the site indicated by ☆, as this 
band is also observed in lane 1 (control).45 
strands by conjugate 4 terminates transcriptional elongation, 
which is also supported by the fact that other retarded bands on the 
gels of Figure 4b and c amount to ones indicating non-specific 
alkylation on the gel of Figure 3b. Conversely, little appearance of 
retarded bands in lanes 6–8 shows that the parent polyamide 15 
dose not inhibit the transcription. This result is consistent with the 
report that polyamides not conjugated with alkylating reagents 
dose not inhibit transcriptions by T7 RNA polymerase in the 
absence of histones.51  
2.4. Binding properties of the parent polyamides to target 
hairpin DNA 
To obtain additional information about the interaction of 
polyamides with the CAG/CTG repeat region, using SPR assays 
we evaluated and compared the binding affinities and kinetics 
parameters of the four parent polyamides 11–13 and 15 (which 
were purified on a reversed-phase flash column and confirmed by 
1H-NMR and ESI-TOF-MS) for a biotinylated hairpin DNA that 
included the target region (5–AGCAGCAGCA–3/5–
Figure 3. Thermally induced strand cleavage of 214 bp DNA fragments derived from 5-Texas Red-labeled strands including (a) a (CAG)12 or (b) (CTG)12 repeat 
(8 nM) by conjugates 3 and 4 at 23°C for 18 h. These two DNA strands are complementary. Lane 1: DNA control; lanes 2–5: 2.5, 5, 10, and 20 nM of 4; lanes 6–
9: 2.5, 5, 10, and 20 nM of 3. (c) Schematic representation of the recognition and alkylation models of these conjugates with two binding modes. The arrows 
indicate the alkylating sites within the target region that were inferred from the sequencing gel analysis. The underlined sites show the ones at which the conjugates 
can alkylate with two binding modes. Note that alkylation does not occur at the site indicated by ☆, as this band is also observed in lane 1 (control).45 
TGCTGCTGCT–3) (Figure 5a).52,53 The 
solution of each polyamide in HBS buffer 
with 0.1% DMSO flowed on a sensor chip 
onto which the designed hairpin DNA was 
immobilized, and the interaction was 
visualized as a sensorgram (Figure 5b–e). 
The values of ka, kd, and KD obtained by 
curve fitting are shown in Table 1. In terms 
of the influence of the recognition length 
over binding affinity, the results of this 
experiment showed that 12 had about 4 
times higher binding ability, which means 
the lower KD values, than that of 13, mainly 
owing to the difference in the rates of 
association (ka). One possible explanation 
for this observation is that it is more difficult 
for 13 to penetrate into the DNA minor 
groove of the target sequence with the closed 
state (hairpin conformation), because of its 
flexibility resulting from the long-chain. 
Another possibility of the stronger binding 
by 12 is that although this polyamide 
interacts with the DNA with the 1:1 binding 
mode, it has two matching positions in the 
target region. This facilitates the penetration 
of the polyamide, which is reflected in the ka 
value. Concerning the rates of dissociation 
(kd), we observed that the extension of the 
recognition length results in a small decrease 
in the kd values. This indicates that the 
increase in the hydrogen bonds from 7 bp 
recognition does not affect the tendency to 
localize at the target region in the DNA 
minor groove, even with the introduction of 
the cationic amino substituent (polyamide 
15). Conversely, comparing the binding 
affinity of 13 and 15 allowed us to 
investigate the effect of a chiral substitution 
on the -turn with an amino group, and 
revealed that 15 had about 5 times higher 
binding ability than that of 13. Particularly, we observed the 
difference in the ka values, suggesting that 15 is more likely to 
access the DNA with the cationic amino group positioned in the 
DNA minor groove to give better electrostatic attraction, retaining 
the forward hairpin folding of 15.43 Since Polyamide 11 was 
designed to bind to the target region with a dimer conformation, 
the sensorgram obtained for 11 was fitted to 2:1 stoichiometry 
binding model that represents dynamics in forming the complexes 
with two polyamides bound side by side in the same region (see 
experimental section).26,27,52 As seen in Table 1, the value of KD2 
(1.3×10-8 M) is lower than that of KD1 (6.1×10-7 M), indicating 
the cooperative binding for the target region. In order to compare 
the other KD values that were obtained by fitting to the 1:1 binding 
model,   a (KD1•KD2)1/2 value was used, which is the value adjusted 
to a per bound molecule.52 As a result, the value for 11 (8.9×10-8 
M) was the highest of those in this experiment, which 
corresponded to lower alkylating activity and specificity.  
3. Conclusion 
We rationally designed and readily synthesized PI polyamide–
Chl conjugates targeting CAG/CTG repeat sequences with 
different lengths or structures. In particular, by introducing the 
novel building blocks that were synthesized in solution phase to 
Fmoc SPPS, we prepared long-chain hairpin PI polyamides which 
otherwise would be difficult to synthesize. The sequencing gel 
analysis demonstrated that the long-chain hairpin PI polyamide 
conjugates showed sequence-specific alkylation at the N3 
adenines or guanines in the CAG/CTG repeat sequence. In vitro 
transcription assays demonstrated that sequence-specific 
alkylation by a PI polyamide–Chl conjugate terminated the 
progression of RNA polymerase at the alkylating sites. The chiral 
substitution on the -turn with an amino group enhanced the 
binding affinity observed in SPR assays. These in vitro 
experiments revealed that conjugate 4 was most appropriate for 
targeting CAG/CTG repeat sequences in terms of chemical 
activity. The propensity of conjugate 4 to specifically alkylate both 
strands suggests the possibility of selective DNA damage, which 
thus may lead to the deletion of expanded CAG/CTG repeat 
sequences within the nucleus. Based on its property of the 
transcriptional inhibition by specific alkylation at both the CAG 
and CTG repeat regions, conjugate 4 may have potency of 
efficiently preventing the elongation of CAG and CTG repeat 
sequences and the accumulation of expanded rCUG repeat 
transcripts and polyglutamine tracts. Moreover, as reported 
previously,41 the concept that building blocks are prepared in 
solution phase to provide relatively long polyamides can be 
applied not only to this case, but also to various cases of targeting 
repeated sequences.  
4. Experimental section 
4.1. General 
Figure 4. Transcribed DNA sequences and transcription products. (a) Sequence A has a template strand 
that contains a (CAG)12 repeat and Sequence B has one that contains a (CTG)12 repeat. The numbers 
indicate position of bases in the sequence from the beginning of transcription. Bold domains indicate the 
inserted (CAG/CTG)12 repeat sequence. The arrows show probably alkylated bases. (b and c) Effects on 
transcription of conjugate 4 and its parent polyamide 15; (b) Sequence A and (c) Sequence B. Lane 1: 
without any polyamides; lanes 2–4: 10, 20, and 30 nM of 4; lane 5: ssRNA markers, lanes 6–8: 10, 20, 
and 30 nM of 15. 
1H NMR spectra were recorded on JEOL JNM ECA-600 
spectrometer (600 MHz for 1H), with chemical shifts reported in 
parts per million relative to residual solvent and coupling constants 
in hertz. The following abbreviations were applied to spin 
multiplicity: s (singlet), brs (broad singlet), d (doublet), t (triplet), 
q (quartet), and m (multiplet). HPLC analysis was performed on a 
Jasco Engineering PU-2080 plus series system using a 150 × 4.6 
mm X-Terra MS C18 reversed-phase column in 0.1% TFA in water 
with acetonitrile as the eluent at a flow rate of 1.0 mL/min and a 
linear gradient elution of 0 to 100% acetonitrile in 20 or 40 min 
with detection at 254 nm. Collected fractions were analyzed 
byESI-TOF-MS (Bruker). Reversed-phase flash column  
chromatography was performed on CombiFlash Rf (Teledyne Isco, 
Inc.) using a 4.3 g reversed-phase flash column (C18 RediSep Rf) 
in  0.1% TFA in water with acetonitrile as the eluent at a flow rate 
of 18.0 mL/min and a linear gradient elution of 0 to 35% 
acetonitrile in 5 to 40 min with detection at 254 nm. HPLC 
purification was performed with a Jasco Engineering UV2075 
HPLC UV/VIS detector and a PU- 2080 plus series system using 
a 150 × 4.6 mm Chemcobond 5-ODS-H reversed-phase column 
in 0.1% TFA in water with acetonitrile as the eluent at a flow rate 
of 1.0 mL/min and a linear gradient elution of 30 to 75% 
acetonitrile in 30 min with detection at 254 nm. Polyacrylamide 
gel electrophoresis was performed on a HITACHI SQ5500-S 
DNA sequencer. Long Ranger gel solution (50%) was purchased 
from FMC bioproducts. Calf thymus DNA (10 mg/mL, 1 µL) was 
purchased from Invitrogen and Thermo Sequence core sequencing 
kit was from GE Healthcare. Loading dye was composed of 10 mL 
of formamide, 200 μL of H2O, 300 μL of a 0.5 M EDTA 2Na in 
H2O (Nacalai Tesque Inc.), and 2.5 mg of new fuchsin (Merck). In 
vitro transcription assays were carried out by in vitro Transcription 
T7 Kit (Takara Bio Inc.) and the transcripts were investigated on 
10 % TBE-Urea Gels containing 7 M urea (Invitrogen). SPR 
assays were performed with a Biacore X system (GE Healthcare), 
and processing of data was carried out by using BIA evaluation, 
version 4.1. Chlorambucil (Chl) was purchased from Sigma, and 
BocHN-β-alanine, 3,3′-diamino-N-methyldipropylamine 
(DMDPA) and 10% Pd/C were from Aldrich. Fmoc-β-Wang resin 
(0.55 mmolg-1) and O-(1H-6-Chlorobenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) were 
purchased from Peptide International. FmocHN-P-CO2H, 
FmocHN-I-CO2H, O2N-I-COCl3, N,N-dimethylformamide (DMF), 
1-methyl-2-pyrrolidone (NMP), and piperidine were purchased 
from Wako, and Boc-D-Dab-OH was from Watanabe Chemical 
Ind., Ltd. PyBOP were purchased from Novabiochem. 
Diisopropylethylamine (DIEA), 4-amino-n-butyric carboxylic 
acid (GABA) were purchased from Nacalai Tesque, Inc. 
Trifluoroacetic acid (TFA) was purchased from Kanto Chemical 
Co., Inc. Dichloromethane (DCM) was purchased from Sasaki 
chemical co., Ltd. The other reagents and solvents were purchased 
from standard suppliers and used without further purification. 
4.2. Syntheses of compound 8-10 
4.2.1. FmocHN-P-γ-CO2H (5) 
Compound 5 was synthesized from FmocHN-P-CO2H. To a 
solvent of DMF was added compound 5 (1.50 g, 4.1 mmol), HCTU 
(1.71 g, 4.1 mmol) and DIEA (1.44 mL, 8.3 mmol), and the 
mixture was stirred at room temperature for 15 min. The reaction 
mixture was added slowly to a solution of GABA (858 mg, 8.3 
mmol) in 1.4 mL DIEA and 10 mL DMF, and it was stirred at room 
temperature for 3 h. After concentration, the oil residue was 
dissolved in the minimum amount of DCM, washed with diethyl 
ether. After the supernatant was removed, to the residue was added 
a large amount of water to afford the precipitation. It was filtered 
and then dried in vacuo to obtain 5 as a brown powder (1.73 g, 
94%). The compound was used in the solid-phase synthesis 
without further purification. 1H NMR (600 MHz, DMSO-d6) δ 
9.42 (s, 1H, NH), 8.31 (brs, 1H, NH), 7.90 (d, J = 7.1 Hz, 2H, CH), 
7.73 (d, J = 7.5 Hz, 2H, CH),7.42 (t, J = 7.5 Hz, 2H, CH), 7.34 (t, 
J = 7.6 Hz, 2H, CH), 6.85 (s, 1H, CH), 6.65 (s, 1H, CH), 4.40 (d, 
J = 6.8 Hz, 2H, CH2), 4.27 (t, J = 6.8 Hz, 1H, CH), 3.76 (s, 3H, 
NCH3), 3.14 (m, 2H, CH2), 2.16 (brs, 2H, CH2), 1.67 (m, 2H, CH2), 
ESI-MS m/z calcd for C25H25N3O5 [M+H]
+ 448.1872; found 
448.1869. 
4.2.2. Boc-D-Dab (FmocHN-P)-CO2H (6) 
Compound 8 was synthesized from FmocHN-P-CO2H. To a 
solvent of 5 mL DMF was added FmocHN-P-CO2H (300 mg, 0.83 
mmol), PyBOP (431 mg, 0.83 mmol) and DIEA (0.40 mL), and 
the mixture was stirred at room temperature for 1 h. To the reaction 
mixture was added Boc-D-Dab-OH (190 mg, 0.87 mmol) and 2 
mL DMF, and then it was stirred at room temperature for 3 h. After 
concentration, the oil residue was dissolved in the minimum 
amount of ethyl acetate, washed with diethyl ether. After the 
supernatant was removed, to the residue was added a large amount 
of water to afford the precipitation. It was filtered and then dried 
in vacuo to obtain 6 as a brown powder (478 mg, quant). The 
compound was used in the solid-phase synthesis without further 
purification. 1H NMR (600 MHz, CDCl3), δ 7.77 (d, 2H, J = 7.6 
Hz, CH), 7.61 (d, 2H, J = 6.9 Hz, CH), 7.40 (t, 2H, J = 7.2 Hz, 
CH), 7.31 (t, 2H, J = 7.2 Hz, CH), 6.85 (s, 1H), 6.63 (s, 1H), 6.54 
(s, 1H), 5.57 (d, 1H, J = 6.2 Hz, NH), 4.48 (d, 2H, J = 6.2 Hz, CH2), 
Determined by fitting to a1:1 binding model with drifting baseline, b1:1 
binding model with mass transfer, or c2:1 binding with mass transfer using 
BIAevaluation 4.1 program to give better fitting. dThe closeness of fit is 
described by the statistical value χ2. 
Figure 5. SPR assays to evaluate the binding affinity of the parent polyamides 
11–13 and 15 to that designed hairpin DNA oligomer containing CAG/CTG 
repeats which was immobilized on a sensor chip. (a) A biotinylated DNA 
oligomer used in this study. SPR response curves of the interaction of the parent 
polyamides at various concentrations with the hairpin DNA immobilized on a 
sensor chip. From the top, concentration: (b) 3200, 1600, 800, 400, and 200 
nM; (c) 500, 250, 125, 62.5, and 31.25 nM; (d) 1000, 500, 250, 125, and 62.5 
nM; (e) 200, 100, 50, 25, and 12.5 nM, respectively. 
 
Table 1. The values of affinities and kinetics parameters by curve fitting for 
each sensorgam. 
PI polyamide ka/M-1s-1 kd/s-1 KD/M χ2d 
11c 
ka1 = 8.8×103 
ka2 = 4.4×102 
kd1 = 5.4×10-3 
kd2 = 5.7×10-6 
KD1 = 6.1×10-7 
KD2 = 1.3×10-8 
2.3 
12a 1.2×105 1.6×10-3 1.4×10-8 7.5 
13b 2.3×104 1.2×10-3 5.3×10-8 4.1 
15b 8.5×104 9.5×10-4 1.1×10-8 3.8 
 
4.34 (d, 2H, J = 6.9 Hz), 4.23 (t, 1H, J = 6.2 Hz, CH), 3.83 (s, 3H, 
NCH3), 3.76 (m, 1H, CH), 3.68 (m, 1H, CH), 3.17 (m, 1H, CH), 
2.02 (m, 1H, CH), 1.95 (m, 1H, CH), 1.43 (s, 9H, CH3), ESI-MS 
m/z calcd for C30H34N4O7 [M+H]
+ 563.2506; found 563.2491. 
4.2.3. BocHN-β-I-CO2Me (8) 
Compound 8 was synthesized from O2N-I-COCl3. Compound 
7 was prepared from O2N-I-COCl3 by 2 steps using much the same 
method as a previously reported one.54 To a DMF solvent (12 mL) 
was added compound 7 (1.37 g, 8.83 mmol), BocHN-β-alanine 
(1.68g, 8.86 mmol), HCTU (3.85 g, 9.30 mmol), DIEA (3.10 mL, 
17.7 mmol), and the solution was mixed and stirred at room 
temperature for 1.5 h. After concentration, a large amount of water 
was added to the oil residue to produce the precipitation. It was 
filtered and dried in vacuo to afford 8 as a white powder (2.44 g, 
7.46 mmol, 84%). The compound was used in the next reaction 
step without further purification. 1H NMR (600 MHz, CDCl3) δ 
8.45 (s, 1H, NH), 7.67 (d, J = 1.4 Hz, 1H, CH ), 7.49 (s, 1H, NH), 
4.00 (s, 3H, OCH3), 3.95 (s, 3H, NCH3), 3.49 (q, J = 6.2 Hz, 
2H,CH2), 2.63 (t, J = 6.22 Hz, 2H CH2), 1.42 (s, 9H, CH3). 
4.2.4. FmocHN-P-β-I-CO2H (10)  
TFA (2.4 mL) was used in the deprotection of a Boc group that 
belongs to compound 8 (1.23 g, 3.75 mmol), and it was then 
evaporated. To a solution of obtained crude in H2O/MeOH (1:1, 
total 20 mL) was added NaOH (1.26 g), and the solution was 
stirred at 40℃ for 2 h. After MeOH was removed from the reaction 
mixture by an evaporator, it was neutralized by 6N HClaq and 
concentrated in vacuo to afford crude gelatinous 9. To a solution 
of an intact 9 in DMF (5 mL) was added a solution of FmocHN-P-
CO2H (816 mg, 2.25 mmol), HCTU (932 mg, 2.25 mmol) and 
DIEA (1.3 mL) in DMF (10 mL) which was stirred at room 
temperature for 1 h, and the reaction mixture was stirred at room 
temperature for 5 h. After a sault was removed from the reaction 
mixture by filtration, a large amount of water was added to the oil 
residue obtained to produce the precipitation. The crude obtained 
by filtration was dissolved in a minimum amount of DCM and 
added diethyl ether to be precipitated again. The pellet by a 
centrifuge was collected and dried in vacuo to afford 10 as a pale 
brown powder (1.07 g, 1.93 mmol, 73%). The compound was used 
in the solid-phase synthesis without further purification. 1H NMR 
(600 MHz, DMSO-d6) δ 9.50 (s, 1H, NH), 9.40 (s, 1H, NH), 8.01 
(s, 1H, NH), 7.90 (d, J = 7.6 Hz, 2H, CH), 7.72 (d, J = 7.5 Hz, 2H, 
CH), 7.42 (t, J = 7.6 Hz, 2H, CH), 7.33 (t, J = 7.6 Hz, 2H, CH), 
7.20 (s, 1H, CH), 6.86 (s, 2H, CH), 4.41 (d, J = 6.2 Hz, 2H, CH2), 
4.26 (t, J = 6.8 Hz, 1H, CH), 3.95 (s, 3H, NCH3), 3.77 (s, 3H, 
NCH3), 3.48 (m, 2H, CH2), 2.52 (t, J = 2.0 Hz, 2H, CH2), ESI-MS 
m/z calcd for C29H28N6O6 [M+H]
+ 557.2149; found 557.2137.   
4.3. Syntheses of parent PI polyamides and their chlorambucil 
conjugate 
4.3.1. General Procedures of Fmoc Solid-phase Peptide 
Synthesis 
Synthesis of each polyamide was performed on a PSSM-8 
(Shimadzu) computer-assisted operation system on a 0.03 mmol 
scale by using Fmoc Chemistry. An Fmoc building block (0.20 
mmol) in each step was set up to solve by NMP on the synthetic 
line. The synthetic procedure of all PI polyamides was as follows; 
twice deblocking for 4 min with 20% piperidine/DMF (0.6 mL), 
activating for 2 min with HCTU (88 mg, 0.21 mmol) in NMP (1 
mL) and 10% DIEA/DMF (0.4 mL), coupling for 60 min, and 
washing with DMF. All coupling were carried out with a single-
coupling cycle. Building blocks used in this study are FmocHN-P-
CO2H (77 mg), FmocHN-I-CO2H (77 mg), and compound 10 (70 
mg) for synthesis of polyamide 11; FmocHN-P-CO2H (77 mg), 
FmocHN-I-CO2H (77 mg), compound 5 (70 mg), and compound 
10 (70 mg) for synthesis of polyamide 12 and 13; FmocHN-P-
CO2H (77 mg), FmocHN-I-CO2H (77mg), compound 6 (70 mg), 
and compound 10 (70 mg) for synthesis of polyamide 14. At the 
last capping process, the samples were washed with 20% acetic 
acid in DMF (1 mL). All lines are purged with solution transfers 
and bubbled by N2 gas for stirring the resin. After the completion 
of the synthesis, the resin was washed with DMF (2 mL) and 
methanol (2 mL) and then dried in a desiccator at room 
temperature in vacuo. 
4.3.2. AcIP-β-IP-β-(CH2)3-NCH3-(CH2)3-NH2 (11) 
Using a 43 mg Fmoc-β-Wang resin (0.55 mmol/g) and a novel 
building block 10, compound 11 was synthesized in a stepwise 
reaction by Fmoc solid-phase protocol described above. After 
resulting AcIP-β-IP-β-wang resin was cleaved with 200 µL of 
DMDPA for 3 h at 55°C, the solvent was evaporated. The residue 
was dissolved in the minimum amount of DCM and subsequently 
washed with diethyl ether to yield a 15.1 mg white solid, which 
was used in next coupling reaction without further purification.  
For SPR assays, the crude compound was purified by reversed-
phase flash column chromatography (water with 0.1% TFA 
containing 0–35% CH3CN over a linear gradient in 5 to 40 min). 
The peak around 23 min was collected and lyophilized to produce 
11 (6.6 mg, 7.9 µmol, 23%) as a yellow solid. 1H NMR (600 MHz, 
DMSO-d6) δ 10.28 (s, 1H, NH) 10.23 (s, 1H, NH) 9.93 (s, 1H, NH) 
9.90 (s, 1H, NH) 8.09-8.05 (m, 3H, NH) 7.45 (s, 1H, CH) 7.41 (s, 
1H, CH) 7.22 (d, 1H, J = 1.4 Hz, CH) 7.20 (s, 1H, CH) 6.93 (s, 2H, 
CH) 3.94 (s, 1H, NCH3) 3.93 (s, 1H, NCH3) 3.81 (s, 1H, NCH3) 
3.80 (s, 1H, NCH3) 3.42 (m, 6H, CH2) 2.87 (br, 3H, CH3) 2.77-
2.73 (m, 6H, CH2) 2.59 (t, J = 6.8 Hz, 2H, CH2) 2.35 (t, 2H, J = 
7.5 Hz, CH2) 2.02 (s, 3H, CH3) 1.77 (m, 4H, CH2 ), ESI-MS m/z 
calcd for C37H53N15O7 [M+2H]
2+ 410.7205; found 410.7201. 
4.3.3. AcIP-β-IP-β-(CH2)3-NCH3-(CH2)3-NH-Chl (1) 
To a solution of the crude compound 11 (2.0 mg) in DMF (200 
µL), PyBOP (5.1 mg, 10 µmol), DIEA (1.7 µL, 10 µmol) and 
chlorambucil (3.1 mg, 10 µmol) were added. The reaction mixture 
was incubated for overnight at room temperature. Evaporation of 
the solvent gave a yellow crude, which was washed with ether and 
DCM and subsequently was purified by HPLC using a 
Chemcobond 5-ODS-H column (water with 0.1% TFA/MeCN 30-
75％ linear gradient, 0-30 min, detected at 254 nm), to produce 1 
(1 mg, 0.91 µmol) as a pale yellow powder. ESI-MS m/z calcd for 
C51H72Cl2N16O8 [M+2H]
2+ 553.2548; found 553.2527. 
4.3.4. AcIP-β-IP-γ-IP-β-IP-β-(CH2)3-NCH3-(CH2)3-NH2 (12) 
Using a 45 mg Fmoc-β-Wang resin (0.55 mmol/g) and two 
novel building blocks 5 and 10, compound 12 was synthesized in 
a stepwise reaction by Fmoc solid-phase protocol described above. 
A subsequent synthetic procedure similar to that used for the 
preparation of compound 11 provided compound 12 (3.6 mg, 2.5 
µmol, 10%) as a yellow powder. 1H NMR (600 MHz, DMSO-d6) 
δ 10.29 (s, 1H, NH) 10.27 (s, 1H, NH) 10.25 (s, 1H, NH) 10.23 (s, 
1H, NH) 9.96-9.92 (m, 4H, NH) 8.09-8.06 (m, 5H, NH) 7.45(s, 2H, 
CH) 7.43 (s, 1H, CH) 7.40 (s, 1H, CH) 7.22 (s, 1H, CH) 7.21 (s, 
1H, CH) 7.20 (s, 2H, CH) 6.95 (s, 1H, CH) 6.93 (s, 3H, CH) 3.94-
3.93 (m, 12H, NCH3) 3.81 (s, 6H, NCH3) 3.80 (s, 6H, NCH3) 3.42 
(m, 8H, CH2) 3.19 (t, J = 6.2 Hz, 2H, CH2 ) 2.86 (s, 3H, NCH3) 
2.75-2.73 (m, 6H, CH2) 2.59 (t, J = 7.6 Hz, 6H, CH2) 2.38 (m, 1H, 
CH2) 2.01 (s, 3H, CH3) 1.78-1.76 (m, 6H, CH2), ESI-MS m/z calcd 
for C66H87N27O13 [M+2H]
2+ 733.8567; found 733.8549. 
4.3.5. AcIP-β-IP-γ-IP-β-IP-β-(CH2)3-NCH3-(CH2)3-NH-Chl (2) 
To a solution of the crude compound 12 (1.9 mg) in DMF (200 
µL), PyBOP (5.9 mg, 12 µmol), DIEA (1.9 µL, 11 µmol) and 
chlorambucil (3.3 mg, 11 µmol) were added. A subsequent 
synthetic procedure similar to that used for the preparation of 
compound 1 provided 2 (0.5 mg, 0.28 µmol) as a pale yellow 
powder. ESI-MS m/z calcd for C80H104Cl2N28O14 [M+2H]
2+ 
876.3910; found 876.3892. 
4.3.6. AcIP-β-IP-β-IP-γ-IP-β-IP-β-IP-β-(CH2)3-NCH3-(CH2)3-
NH2 (13) 
Using a 50 mg Fmoc-β-Wang resin (0.60 mmol/g) and two 
novel building blocks 5 and 10, compound 13 was synthesized in 
a stepwise reaction by Fmoc solid-phase protocol described above. 
A subsequent synthetic procedure similar to that used for the 
preparation of compound 11 provided compound 13 (4.9 mg, 2.4 
µmol, 8%) as a yellow solid. 1H NMR (600 MHz, DMSO-d6) δ 
10.29 (s, 3H, NH) 10.26 (s, 1H, NH) 10.25 (s, 1H, NH) 10.23 (s, 
1H, NH) 9.94 (s, 1H, NH) 9.93 (s, 2H, NH) 9.92 (s, 2H, NH) 9.91 
(s, 1H, NH) 8.07 (m, 7H, NH) 7.44 (s, 3H, CH) 7.43 (s, 1H, 
CH)7.41 (s, 2H, CH) 7.21-7.19 (m, 6H, CH) 6.95-6.93 (m, 6H,CH) 
3.94 (s, 12H, NCH3) 3.93 (s, 6H, NCH3) 3.81 (s, 12H,NCH3) 3.80 
(s, 6H, NCH3) 3.41 (m, 14H, CH2) 2.77-2.72 (m, 6H, CH2) 2.58 (t, 
J = 6.8 Hz, 10H, CH2) 2.37-2.33 (m, 2H, CH2) 2.08 (s, 3H, CH3) 
2.02 (s, 3H, CH3) 1.79-1.75 (m, 6H, CH2), ESI-MS m/z calcd for 
C94H119N39O19 [M+3H]
3+ 700.3260 ; found 700.3239. 
4.3.7. AcIP-β-IP-β-IP-γ-IP-β-IPy-β-IPy-β-(CH2)3-NCH3-
(CH2)3-NH-Chl (3) 
To a solution of the crude compound 13 (2.1 mg) in DMF (200 
µL), PyBOP (3.9 mg, 7.6 µmol), DIEA (1.3 µL, 7.5 µmol) and 
chlorambucil (2.3 mg, 7.6 µmol) were added. A subsequent 
synthetic procedure similar to that used for the preparation of 
compound 1 provided 3 (0.6 mg, 0.25 µmol) as a pale yellow 
powder. ESI-MS m/z calcd for C108H136Cl2N40O20 [M+3H]
3+ 
795.3489 ; found 795.3477. 
4.3.8. Boc-D-Dab (AcIP-β-IP-β-IP)-IP-β-IP-β-IP-β-(CH2)3-
NCH3-(CH2)3-NH2 (14) 
     Using a 44 mg Fmoc-β-Wang resin (0.60 mmol/g) and two 
novel building blocks 6 and 10, compound 14 was synthesized in 
a stepwise reaction by Fmoc solid-phase protocol described above. 
Resulting Boc-D-Dab (AcImPy-β-ImPy-β-ImPy)-ImPy-β-ImPy-
b-ImPy-β-wang resin was cleaved with 200 µL of DMDPA and 
100 µL DMF for 3 h at 45°C, the solvent was evaporated and the 
residue was dissolved in the minimum amount of DCM, washed 
with diethyl ether to yield a 18.5 mg white solid, which was used 
in next reactions without further purification. 
4.3.9. AcIP-β-IP-β-IP-D-Dab-IP-β-IP-β-IP-β-(CH2)3-NCH3-
(CH2)3-NH2 (15). 
     To a solution of the crude compound 14 (16.3 mg) in DCM 
(600 µL) was added TFA (400 µL) and the mixture was shook at 
room temperature for 30 min. The mixture was concentrated in 
vacuo and the residue was dissolved in the minimum amount of 
DCM, washed with diethyl ether to afford the oil residue. The 
residue was purified by reversed-phase flash column as mentioned 
above to obtain 15 (3.5 mg, 1.7 µmol) as a yellow solid. ESI-MS 
m/z calcd for C94H120N40O19 [M+3H]
3+ 705.3296 ; found 705.3255. 
4.3.10. AcIP-β-IP-β-IP-D-Dab-IP-β-IP-β-IP-β-(CH2)3-NCH3-
(CH2)3-NH-Chl (4) 
     To a solution of the crude compound 14 (16.3 mg) in DMF (1 
mL), PyBOP (41.8 mg, 80 µmol), DIEA (15 µL) and chlorambucil 
(22.6 mg, 74 µmol) were added. The reaction mixture was mixed 
for 9 h at room temperature. Evaporation of the solvent gave a 
yellow residue, which was dissolved in the minimum amount of 
DCM, washed with diethyl ether. It was purified by reverse-phase 
flash column chromatography as mentioned above and the boc 
group was then deprotected with TFA-DCM (1:1, total 2.4 mL) to 
produce the oil residue. It was dissolved in the minimum amount 
of DCM, washed with diethy ether, and purified by HPLC as 
mentioned above to produce 4 (0.7 mg, 0.29 µmol) as a pale yellow 
powder. ESI-MS m/z calcd for C108H137Cl2N41O20 [M+3H]
3+ 
800.3525 ; found 800.3488. 
4.4. Preparation of plasmid containing (CAG/CTG)12 repeat 
sequences 
All DNA fragments and primers for cloning or DNA 
amplification were purchased from Sigma. The 38 bp DNA 
fragments were annealed in a final volume of 50 L containing 10 
M of each strand (5’-(CAG)12CA-3’ and 5’-G(CTG)12A-3’) and 
ligated into pGEM-T Easy vectors (Promega). Escherichia coli 
JM109 competent cells (Toyobo) were transformed and cultured 
on LB plates with 50 g/mL ampicillin and 32 mg X-gal/400 mg 
IPTG overnight at 37 °C. White colonies were identified by colony 
direct polymerase chain reaction (PCR) in 15 L of 1×Go Taq 
Green Master Mix (Promega) containing 300 nM of primer set 
(T7: 5’-TAATACGACTCACTATAGG-3’, sp6: 5’-
ATTTAGGTGACACTATAGAATAC-3’). The reaction mixture 
was incubated at 95 °C for 3 min then followed by 34 incubation 
cycles of 95 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1 min 
with final extension step of 72 °C for 5 min. The appropriate 
colony was selected for transfer to 5 mL of LB medium with 50 
g/mL ampicillin and cultured overnight at 37 °C overnight. The 
plasmids with inserts were extracted using GenElute Plasmid 
Miniprep Kit (Sigma Aldrich) and their sequences were identified 
by 3130xL Genetic Analyzer (Applied Biosystems). 
4.5. Preparation of 5’-Texas Red-labeled DNA fragments and 
high resolution gel electrophoresis 
The 5’-Texas Red labeled DNA fragments containing the 
CAG/CTG repeat sequence was prepared by PCR using a primer 
set of 5’-Texas Red-labeled T7 and sp6 promoter primer or that of 
T7 and 5’-Texas Red-labeled sp6 promoter primer under the same 
condition and reagents as above. The PCR products were purified 
by GenElute PCR cleanup kit (Sigma Aldrich). The 5’-Texas Red-
labeled DNA fragments were alkylated by various concentrations 
of alkylating polyamides in 10 µL of 5 mM sodium phosphate 
buffer (pH 7.0) containing 10% DMF at 23 °C, for 18 h. The 
reaction was quenched by the addition of calf thymus DNA (10 
mg/mL, 1 µL) and the mixtures were heated at 95 °C for 10 min 
to cleave the DNA strands at the alkylating sites. The DNA was 
recovered by vacuum centrifugation. The pellet was dissolved in 7 
µL of loading dye (formamide with New fuchsin), heated at 95 °C 
for 25 min, and then immediately chilled on ice. The 1.8 µL aliquot 
was subjected to electrophoresis on a 6% denaturing 
polyacrylamide gel using a HITACHI SQ5500-E DNA Sequencer. 
4.6. In vitro transcription assays 
DNA fragments including (CAG/CTG)12 repeats for RNA 
transcription was prepared from the plasmids, which is described 
above, by PCR-amplification using 1X Go Taq Green Master Mix 
containing T7 promoter primer (5’-
TAATACGACTCACTATAGG-3’) and sp6 promoter primer (5’-
ATTTAGGTGACACTATAGAATAC-3’). The reaction mixture 
was incubated at 95 °C for 3 min then followed by 30 incubation 
cycles of 95 °C for 30 sec, 50 °C for 30 sec, and 72 °C for 30 sec. 
After incubation, the PCR products were purified by QIAquick 
Gel Extraction Kit (Qiagen) and QIAquick Nucleotide Removal 
Kit (Qiagen). The obtained DNA fragments (8 nM) were incubated 
with various concentrations of 4 and 15 in a 5 mM sodium 
phosphate buffer (pH 7.0) containing 10 % DMF at the room 
temperature for 18 h. The alkylation reagents were quenched by 
the addition of DNA oligomer (200 µM, 2 µL).The reaction 
mixtures were purified by illustra MicroSpin G-25 Columns (GE 
Healthcare) and then lyophilized for 3 h. The DNA fragments were 
transcribed with in vitro Transcription T7 Kit (Takara Bio Inc.).  
After transcriptions, the remaining DNA fragments were digested 
by RNase free DNase I (10 Units) included in the transcription kit 
for 30 min at 37 °C and the obtained RNAs were purified by 
RNeasy Mini Kit (Qiagen). Transcription products were analyzed 
by PAGE at 180 V for 80 min using 10 % TBE-Urea Gels 
containing 7 M urea (Invitrogen) and detected by SYBR Gold 
(Applied Biosystems). Before loading, samples were dissolved in 
TBE Urea Sample Buffer (Invitrogen), heated for 5 min at 95 °C, 
and then immediately cooled on ice for a few minutes. Low Range 
ssRNA Ladder (New England Biolabs) was used as a RNA marker 
and this was heated and then cooled similarly in loading buffer 
included in the ladder set. The bands were photographed and 
analyzed with Fluoro Image Analyzer FLA-3000GF (Fujifilm). 
4.7. SPR assays 
SPR experiments were performed on a Biacore X instrument. 
A biotinylated hairpin DNA was purchased from Sigma and the 
hairpin DNA is shown in Figure 5a. A streptavidin-functionalized 
SA sensor chip was purchased from Biacore. The biotinylated 
DNA is immobilized to the chip to obtain the desired 
immobilization level (approximately 1200 RU rise). SPR assays 
were carried out using HBS-EP buffer (10 mM HPES pH 7.4, 150 
mM NaCl, 3mM EDTA, and 0.005％ Surfactant P20) with 0.1％ 
DMSO at 25°C. A series of sample solutions with various 
concentrations were prepared in the buffer with 0.1％ DMSO and 
injected at a flow rate of 20 ml/min. To measure the values of 
binding affinity and kinetics parameter, data processing was 
performed with an appropriate fitting model using BIAevaluation 
4.1 program. The predefined models (1:1 binding model with mass 
transfer or with drafting baseline) were used for fitting the 
sensorgrams of polyamide 12, 13, and 15 to give better fitting. For 
polyamide 11, in order to represent dynamics in forming the 
complexes with two polyamides bound side by side in the same 
region, the sensorgram was fitted with the following model (eq 1): 
A and Conc A correspond to the polyamide close to the surface 
which is capable of binding to the DNA ligand and the bulk 
concentration of the polyamide. ka1 and ka2 represent the rates of 
association of the first and second polyamide with the ligand, 
respectively; kd1 and kd2 represent the rates of dissociation of the 
polyamide from a 1:1 complex and 2:1 complex, respectively. kt is 
the empirical constant for mass transfer. The closeness of the fit is 
described by the statistical value 𝜒2 (eq 2): 
 
 
where is the fitted value at a given point, 𝑟𝑥 is the experimental 
value at the same point, 𝑛 is the number of data points, and 𝑝 is the 
number of fitted parameters  
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